Exelixis, Inc. (�Exelixis,� �we,� �our� or �us�) is a biotechnology company
committed to developing small molecule therapies for the treatment of cancer.
Our two most advanced assets, COMETRIQ� (cabozantinib), our wholly-owned
inhibitor of multiple receptor tyrosine kinases, and cobimetinib
(GDC-0973/XL518), a potent, highly selective inhibitor of MEK, which we
out-licensed to Genentech, Inc. (a wholly-owned member of the Roche Group), or
Genentech, are currently the subject of six ongoing phase 3 pivotal trials.
Top-line results from four of these pivotal trials are expected in 2014.
We are focusing our proprietary resources and development and commercialization
efforts primarily on COMETRIQ (cabozantinib), which was approved on November 29,
2012, by the U.S. Food and Drug Administration, or FDA, for the treatment of
progressive, metastatic medullary thyroid cancer, or MTC, in the United States,
where it became commercially available in late January 2013.